Table A2.
Baseline patient and tumor characteristics according to PD-L1 TPS status prior to neoadjuvant CRT.
| Parameter | PD-L1 TPS ≤1% N = 17 (%) |
PD-L1 TPS >1% N = 48 (%) |
p-Value |
|---|---|---|---|
| Age | 0.755 | ||
| ≤65 years | 11 (65) | 29 (60) | |
| >65 years | 6 (35) | 19 (40) | |
| Sex | 0.368 | ||
| female | 4 (23) | 17 (35) | |
| male | 13 (77) | 31 (65) | |
| cTNM stage | 0.559 | ||
| I | 0 (0) | 1 (2) | |
| II | 9 (53) | 19 (40) | |
| III | 8 (47) | 28 (58) | |
| cT stage | 0.662 | ||
| T2 | 1 (6) | 1 (2) | |
| T3 | 14 (82) | 43 (90) | |
| T4 | 2 (12) | 4 (8) | |
| cN stage | 0.422 | ||
| N- | 9 (53) | 20 (42) | |
| N+ | 8 (47) | 28 (58) | |
| Histologic grade | 0.230 | ||
| I | 1 (6) | 0 (0) | |
| II | 14 (82) | 42 (91) | |
| III | 2 (12) | 4 (9) | |
| NA | 0 | 2 | |
| Lymphovascular invasion | 0.657 | ||
| no | 11 (85) | 30 (79) | |
| yes | 2 (15) | 8 (21) | |
| NA | 4 | 10 | |
| Venous invasion | 0.069 | ||
| no | 10 (83) | 38 (97) | |
| yes | 2 (17) | 1 (3) | |
| NA | 5 | 9 |
PD-L1: programmed death-ligand 1; TPS: tumor proportion score.